

Resource Summary Report

Generated by [NIF](#) on Sep 17, 2026

NCI-H820

RRID:CVCL_1592

Type: Cell Line

Proper Citation

RRID:CVCL_1592

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1592

Proper Citation: RRID:CVCL_1592

Description: Cell line NCI-H820 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung papillary adenocarcinoma

Defining Citation: [PMID:1311061](#), [PMID:1565469](#), [PMID:2386953](#), [PMID:8626706](#), [PMID:8806092](#), [PMID:11030152](#), [PMID:20557307](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31803961](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H820

Synonyms: H820, H-820, NCIH820

Cross References: BTO:BTO_0006024, CLO:CLO_0008119, EFO:EFO_0003125, ArrayExpress:E-MTAB-2706, ATCC:HTB-181, BioGRID_ORCS_Cell_line:1442, BioSample:SAMN03473295, cancercellines:CVCL_1592, Cell_Model_Passport:SIDM00019, CLS:305841, Cosmic:903579, Cosmic:1028945, Cosmic:1128247, Cosmic:1129778, Cosmic:1146923, Cosmic:1333019, Cosmic:1802301, Cosmic:2125259, DepMap:ACH-001140, EGA:EGAS00001000610, GEO:GSM108855, GEO:GSM108856, GEO:GSM434282, GEO:GSM784252, GEO:GSM794301,

GEO:GSM817078, IARC_TP53:528, IGRhCellID:H820GEO,
PharmacoDB:NCIH820_1140_2019, Progenetix:CVCL_1592, Wikidata:Q54908126

ID: CVCL_1592

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260913T004957+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H820.

No alerts have been found for NCI-H820.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Sakai T, et al. (2025) Utility of CK8/18 in identifying circulating tumor cells derived from lesions in patients with non-small cell lung cancer. Translational lung cancer research, 14(6), 2100.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. International journal of cancer, 154(6), 1029.

Poliakov?? Turan M, et al. (2024) E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network. Cancer research communications, 4(7), 1863.

Kang J, et al. (2022) EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer. Cell reports, 41(11), 111827.

Yenerall P, et al. (2020) RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. Cell chemical biology, 27(1), 105.

Ge P, et al. (2019) miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer. BMC cancer, 19(1), 1203.